<DOC>
	<DOCNO>NCT00697073</DOCNO>
	<brief_summary>This study mean assess safety tolerability idebenone patient Friedreich 's Ataxia 12 month period .</brief_summary>
	<brief_title>Study Assess Safety Tolerability Idebenone Treatment Friedreich 's Ataxia Patients</brief_title>
	<detailed_description>The study involve 6 clinic visit .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Inclusion criterion : Friedreich 's ataxia patient complete core study SNTIII002 ( NCT00537680 ) present Week 24 ( Visit 5 ) study Body weight â‰¥ 25kg/55 lbs Negative urine pregnancy test Patients opinion investigator able comply requirement study Exclusion criterion : Adverse event course SNTIII002 ( NCT00537680 ) opinion investigator attributable idebenone preclude treatment idebenone Clinically significant abnormality clinical hematology biochemistry include , limited , elevation great 2 time upper limit normal AST , ALT creatinine Treatment coenzyme Q10 , vitamin E ( take dose 5 time daily requirement ) source idebenone within past month Parallel participation another clinical drug trial Past present history abuse drug alcohol Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Friedreich 's Ataxia</keyword>
	<keyword>Idebenone</keyword>
	<keyword>ICARS</keyword>
</DOC>